MEI Pharma, Inc. (MEIP)

NASDAQ: MEIP · IEX Real-Time Price · USD
7.50
-0.05 (-0.66%)
At close: Jun 2, 2023, 4:00 PM
7.60
+0.10 (1.33%)
After-hours: Jun 2, 2023, 6:53 PM EDT
-0.66%
Market Cap 49.97M
Revenue (ttm) 58.77M
Net Income (ttm) -37.87M
Shares Out 6.66M
EPS (ttm) -5.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,700
Open 7.55
Previous Close 7.55
Day's Range 7.28 - 7.55
52-Week Range 4.00 - 13.60
Beta 1.03
Analysts Buy
Price Target 33.00 (+340.0%)
Earnings Date May 11, 2023

About MEIP

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 19, 2003
Employees 102
Stock Exchange NASDAQ
Ticker Symbol MEIP
Full Company Profile

Financial Performance

In 2022, MEI Pharma's revenue was $40.70 million, an increase of 16.96% compared to the previous year's $34.80 million. Losses were -$54.45 million, 31.8% more than in 2021.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for MEIP stock is "Buy." The 12-month stock price forecast is $33.0, which is an increase of 340.00% from the latest price.

Price Target
$33.0
(340.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection ...

1 day ago - Business Wire

MEI Pharma Board of Directors Rejects Unsolicited Proposal

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that its Board of Directors (the “Board”) reviewed and rejected the unsolicited and non-binding proposal rec...

2 days ago - Business Wire

MEI Pharma Confirms Receipt of Unsolicited Acquisition Proposal

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today confirmed receipt of an unsolicited and non-binding proposal on May 23, 2023 from a group represented by Anson Advisor...

3 days ago - Business Wire
}

MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced an update to the Phase 1 study evalu...

1 week ago - Business Wire

MEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational Highlights

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 3...

3 weeks ago - Business Wire

MEI Pharma Announces 1-for-20 Reverse Stock Split

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its board of directors approved...

1 month ago - Business Wire

SHAREHOLDER ALERT: Weiss Law Investigates Infinity Pharmaceuticals, Inc.

NEW YORK , Feb. 28, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Infinity Pharmaceuticals, Inc. ("Infini...

Other symbols: INFI
3 months ago - PRNewsWire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Infinity Pharmaceuticals, Inc.

NEW YORK , Feb. 23, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and its board of directors concerning the...

Other symbols: INFI
3 months ago - PRNewsWire
}

MEIP STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of MEI Pharma, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of MEI Pharma, Inc. (NASDAQ: MEIP) and Infinity Pharmaceuticals, Inc. is fair to MEI share...

3 months ago - Business Wire

MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates

SAN DIEGO, CA. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmac...

Other symbols: INFI
3 months ago - Business Wire

MEI Pharma Reports Second Quarter Fiscal Year 2023 Results and Operational Highlights

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended Decembe...

4 months ago - Business Wire

MEI Pharma Announces Adjournment of Annual Meeting of Stockholders

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, announced today that its annual meeting of stockholders has been ...

6 months ago - Business Wire

MEI Pharma Initiates Strategic Realignment

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it plans to initiate a realig...

6 months ago - Business Wire
}

MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Jap...

6 months ago - Business Wire

Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in Japan

TOKYO & SAN DIEGO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology...

7 months ago - Business Wire

MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational Highlights

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended September...

7 months ago - Business Wire

MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd.

7 months ago - Business Wire

MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options fo...

8 months ago - Business Wire

MEI Pharma Announces Changes to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Christine A. White, M.D., has decid...

9 months ago - Business Wire

MEI Pharma Reports Fiscal Year 2022 Results and Operational Highlights

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30...

9 months ago - Business Wire

MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright...

9 months ago - Business Wire

MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2022 f...

9 months ago - Business Wire

MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 415...

11 months ago - Business Wire

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry...

1 year ago - Business Wire

MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress

SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 415...

1 year ago - Business Wire